先聲藥業(02096.HK)抗新冠創新藥先諾欣新藥上市申請獲藥監局受理

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)抗新冠創新藥先諾欣新藥上市申請獲藥監局受理

阿思達克 01-16 16:32

先聲藥業(02096.HK)公布，於今日(16日)，集團與中國科學院上海藥物研究所、武漢病毒研究所合作的創新藥先諾欣新藥上市申請獲中國國家藥品監督管理局以藥品特別審批程序受理，擬用於治療輕至中度新型冠狀病毒感染成年患者。先諾欣是一款口服小分子抗新冠病毒創新藥，其中先諾特韋針對SARS-CoV-2病毒複製必須的3CL蛋白(酉每)，與低劑量利托那韋聯用有助於減緩先諾特韋在體內的代謝或分解，提高抗病毒效果。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)抗新冠創新藥先諾欣新藥上市申請獲藥監局受理

Services

About Us

Agreement Statement